Axsome Therapeutics (AXSM) Cash & Equivalents (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Cash & Equivalents data on file, last reported at $305.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 1.4% year-over-year to $305.1 million; the trailing twelve-month figure through Mar 2026 stood at $305.1 million (up 1.4% YoY), and the FY2025 full-year result was $322.9 million, up 2.4% from the prior year.
• Cash & Equivalents declined to $305.1 million in Q1 2026, from $322.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $437.1 million in Q2 2023 to a low of $73.4 million in Q2 2022.
• A 5-year average of $289.4 million and a median of $315.4 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 48.57% in 2022 and jumped 495.57% in 2023, its largest moves.
• Tracing AXSM's Cash & Equivalents over 5 years: stood at $200.8 million in 2022, then soared by 92.29% to $386.2 million in 2023, then declined by 18.34% to $315.4 million in 2024, then increased by 2.4% to $322.9 million in 2025, then decreased by 5.52% to $305.1 million in 2026.
• Business Quant data shows AXSM's Cash & Equivalents at $305.1 million in Q1 2026, $322.9 million in Q4 2025, and $325.3 million in Q3 2025.